Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibutamoren - Lumos Pharma/Merck

Next Previous
Drug Profile

Ibutamoren - Lumos Pharma/Merck

Alternative Names: Ibutamoren mesilate; Ibutamoren mesylate; L 163191; LUM-201; MK-0677; MK-677; Oratrope

Latest Information Update: 29 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Lumos Pharma; Massachusetts General Hospital; Merck & Co
  • Class Antidementias; Hepatoprotectants; Indoles; Osteoporosis therapies; Small molecules; Spiro compounds
  • Mechanism of Action Growth hormone releasing factor agonists; Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Somatotropin deficiency
  • Phase II Non-alcoholic fatty liver disease
  • No development reported Turner's syndrome
  • Discontinued Alzheimer's disease; Fibromyalgia; Fracture; Postmenopausal osteoporosis; Sarcopenia

Most Recent Events

  • 28 Oct 2025 Phase-III clinical trials in Somatotropin deficiency (In children, Treatment-naive) in USA (PO) (NCT06948214)
  • 19 Aug 2025 Lumos Pharma plans a phase-III trial for Somatotropin deficiency (In children, Treatment-experienced) in September 2026 (PO) (NCT07129759)
  • 12 Jul 2025 Phase-I clinical trials in Somatotropin deficiency (In volunteers) (PO) .

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top